When Tivozanib was first discovered

Tivozanib was discovered in Kyowa Kirin and developed by Aveo Pharmaceuticals. The TIVO-1 trial is the first open-label, randomized, controlled, Phase III study to attempt to study the efficacy of tivozanib in advanced renal cell carcinoma (RCC) in eligible patients with renal cell carcinoma with a clear cell component who have undergone prior nephrectomy and who have recurrent or metastatic disease. Tivozanib was associated with progression-free survival of 11.9 months, according to an independent radiology review, and prespecified subgroup analyzes based on baseline characteristics showed a consistent progression-free survival (PFS) advantage for tivozanib. The overall response rate (ORR) of tivozanib was also statistically higher.